immunometabolism-based treatment of autoimmune disease
Istesso's core belief did not move between August 2017 and March 2018. In both statements, the company says autoimmune disease can be treated by reprogramming metabolism. The logic stays the same all the way through: find new approaches to autoimmunity, invent molecules that alter metabolism, restore immune balance, and get patients back to something like normal life. What changed is mostly phrasing. The 2018 version sounds a touch more packaged, with the same idea recast as a discovery and development model. That is a presentation shift, not a scientific one. The target, the mechanism, and the promised patient outcome all stay in place. Evidence is thin because we only have two closely spaced website snapshots, and they say almost the same thing. So the honest read is simple: this is continuity, not evolution. If the company's internal conviction changed during that period, these public statements do not show it.